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ABDOMINAL MULTIVISCERAL TRANSPLANTATION1,2 
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Under FK506·based immunosuppression, 13 abdomi· 
nal multivisceral transplantations were performed in 
6 children and 7 adults. Of the 13 recipients. 7 (53.8%) 
are alive and well with functioning grafts after 9 to 31 
months. Six recipients died: three from PTLD. one 
from rejection. one from sepsis, and one from respira' 
tory failure. In addition to rejection, postoperative 
complications occurring in more than isolated cases 
included PTLD (n=6), abdominal abscess formation 
(n=5), pancreatitis (n=3), and ampullary dysfunction 
(n=2). In addition, infection by enteric microorgan· 
isms was common during the early postoperative pe· 
riod. Currently, all 7 survivors are on an oral diet and 
have normal liver function. Two recipients (one insu· 
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lin·dependent) require antidiabetes treatment, in one 
case following distal pancreatectomy and in the other 
after two episodes of pancreatic rejection. Thus, abo 
dominal multivisceral transplantation is a difficult 
but feasible operation that demands complex and pro· 
longed posttransplantation management. It is not yet 
ready for application and awaits a better strategy of 
immune modulation. 
Abdominal multi visceral transplantation was developed 
experimentally more than 30 years ago ( 1. 2), The procedure 
was extremely difficult, yielding >5-day survival in only 5 of 
39 untreated animals. No clinical application of multi visceral 
transplantation could be envisioned at that time. In 1989, we 
first reported multivisceral transplantation in two children 
who had short bowel syndrome and total parenteral nutrition 
(TPN)* induced liver failure (3). The first patient died during 
• Abbreviations: GVHD, graft·versus-host disease; PTLD, post· 
transplant Iymphoproliferative disorder. TPN, total parenteral 
nutrition. 
> 
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the immediate postoperative period. but the second patient 
survived under cyclosporine-based immunosuppression with 
well-functioning organs for 192 days. Including these two 
cases, eight attempts (4-8) at abdominal multivisceral trans-
plantation under cyclosporine-based immunosuppression 
have been reported. All eight patients died. with the longest 
surviving 320 days. 
With the advent of a new immunosuppressive agent. 
FK506. a clinical trial of intestinal transplantation was in-
stituted at our center in May 1990 ( 71. Promising results with 
these initial cases prompted us once again to attempt ab-
dominal multivisceral transplantation (8. 9). From October 
1991 to the end of 1993.13 patients underwent multivisceral 
transplantation at our center, 10 as a primary procedure and 
3 for the attempted rescue of recipients of less-complex muI-
tivisceral grafts that had failed. Seven recipients are cur-
rently alive for 8 to 30 months. 
MATERIALS AND METHODS 
matientK~K The 13 patients included 6 children who were 5.4::t3.9 
years old and 7 adults WIth a mean age of 32.0::7.1 years tage range 
1.6 years to 44.8 years). Ten were primary recipients. and the other 
3 had already failed a lesser intraabdominal transplant procedure. 
The procedure had to be abandoned in 2 additional candidates be-
cause of excessive bleeding during preliminary dissection of the na-
tive organs; both died. The indications for the 10 primary recipients 
included short bowel syndrome with (n=4) or without (n=3) TPN-
related liver failure. mesenteric venous thrombosis with end-stage 
liver failure (n= ll. juvenile polyposes (n= ll. and malignant endo-
crine tumor (n = 1). Although isolated intestine or combined intestine 
and liver grafting was considered for the short bowel patients. mul-
tivisceral transplantation was chosen because of the existence of 
thromboses of both the celiac axis and the superior mesenteric artery 
(n=3). TPN-related liver and pancreas failure tn=3). and pseudo-
obstruction affecting the entire gastrointestinal tract tn= 1), The 3 
patients undergoing rescue multi visceral transplantation had under-
gone graft removal 2 months previously due to rejection of an iso-
lated intestinal graft (n = 1) or were bearing a rejecting intestine-liver 
In=l) or liver (n=U graft. The last patient also had intestinal 
pseudoobstruction since birth and should have undergone a multi-
visceral transplantation on the first occasion. The features of the 13 
recipients are summarized in Table 1. 
Donor operation. The grafts were obtained for ABO-blood type 
identical cadaveric donors with a mean age of 3.3 ::3.4 years for the 
children and 21.6::tl0.2 for the adults. ranging from 0.6 to 39 years. 
Lymphocytotoxic cross match was strongly positive in 2 recipients; 
one survives after 14 months and the other died of intractable cel-
lular rejection after 58 days. HLA matching was random. Immedi-
ately after the donors were accepted. selective bacterial decontami-
nation was initiated by the method described previously (8). 
Immunomodulation of donors or grafts by irradiation. ALG. or anti-T 
cell monoclonal antibody (OKT3) administration was not attempted. 
The techniques for multi visceral graft harvesting have been de-
scribed before (8. 10). En bloc retrieval of the multivisceral grafts 
includes four steps: dissection from the retropentoneum of the stom-
ach. liver. pancreas. spleen. duodenum. small bowel. and varying 
lengths of the colon; transection of the vena cava above and below the 
liver; removal ofthe celiac axis and the superior mesenteric artery in 
continuity with the anterior wall of the abdominal aorta; and 
transection of the gastrointestinal tract at the abdominal esophagus 
or proximal stomach and at the descending colon distally. University 
of Wisconsin solution (1-2 1) was flushed through the abdominal 
aorta for graft preservation. Splenectomy, Heineke-Mikulicz pyloro-
plasty. and lumenal irrigation WIth 1-2 L cold lactated Ringer's so-
lution were perfonned on the back table. Cold ischemia time from 
clamping of the donor aorta until graft revascularization in the re-
cipient varied from 4.1 hr to 10.8 hr. with a median of 8.3 hr. 
Recipient operation. The operative procedure was similar to that 
used originally in experimental animals 30 years ago (1,2) and in the 
early clinical cases (3)_ In brief. arterial reconstruction was per-
fonned by end-to-side anastomosis of the Carrel patch containing 
both the celiac axis and the superior mesenteric artery to the side of 
the host infrarenal abdominal aorta. The donor thoracic aorta was 
used as an arterial graft. Venous outflow from the graft was via the 
hepatic graft. which was transplanted using the piggy-back method 
(11). Proximal gastrointestinal continuity was reconstructed by 
anastomosing the distal end of the recipient esophagus or the gastric 
stump to the anterior wall of the graft stomach. The tenninal ileum 
(n=3) (Fig. lA). or ascending, transverse. or descending colon (n= 10) 
of the gratts was anastomosed in a side-to-slde or end-to-side fashion 
TABLE 1. Demographics of the 13 abdominal multivisceral transplant recipients 
Preoperative TPNb HospItalizatIon 
Patient Age Indication" Total Gran' SurvlVal d Cause of death Duration leU Discharge rdays) 
rmonthsi bIlirubin ,days) rdays) 
rmg/dl\ 
1 32.6 CA & SMA thrombosis 36 0.5 ~tv without colon 60 196 >944 
2 24.3 CA & SMA thrombosis 3 1.3 ~tv without colon 11 119 >717 
:3 ~KO Failed liver/intestine 50 23 ~ with kidney 23 57 PTLD 
transplantation 
~ :n.5 Volvulus 15 4.6 ~tv without colon ~P 111 >641 
G 4.5 Pseudoobstruction 54 26.1 ~tv 30 151 >559 
6 44.8 Malignant neuroendocrine 0 0.7 ~tv 21 49 PTLD 
tumor 
~ 1.8 Juvemle polyposes 22 0.5 ~tv without liver 17 87 >420 , 
8 :l2.6 Budd-Chiari syndrome 0 3.7 ~fs 120 197 Respiratory failure 
9 10.9 Pseudoobstruction t after 19 0.4 ~fs 7 76 >355 
liver transplantatiOn) 
10 9.3 Volvulus 24 8.3 ~fs 26 no 198 PTLD 
II :l4.9 Gardner's syndrome 26 18.1 ~fs 41 70 >281 
12 23.4 F ailed intestine 163 1.2 ~fs 91 147 SepsIs 
transplantation 
13 1.6 Intestinal atresia 19 58.2 ~fs 58 58 Rejection 
• CA: celiac axlS: SMA: superior mesentenc artery. 
h TPN: total parenteral nutrition . 
. ~: multivisceral grafts include the stomach. liver. pancreas. Intestine. and colon . 
• J As of May 15. 1994. 
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FIGURE 1. Scheme of multivisceral 
transplantation: (A) Multiviscerai 
transplantation without colon; (8) 
Multivisceral transplantation with 
colon; Ie) Multivisceral transplan-
tation without liver and with rectal 
reconstruction by a pull-through C 
technique; (0) Multivisceral trans-
plantation with bilateral kidneys. 
to the prOXimal end of the remaimng recipient colon (Fig. IB l. Cho-
lecystectomy was carried out in all cases. and a catheter was intro-
duced VIa the cystic duct into the common bile duct for biliary de-
compressIOn and postoperative cholangiogram. A tube jejunostomy. 
with termmal ileostomy (n=5). colostomy (n=21. or Bishop-Koop iI-
<,ostomy (n=6 I. was made for entenc decompressIOn. enteral feeding. 
and a route for endoscopic examination. 
:\lodification of the procedure was reqUired in some cases. Because 
of the profuse hemorrhage that precluded the operation in two pa-
tients With mesentenc venous thromboses. the celiac axis and the 
supenor mesentenc artery were occluded in Case tI by anglographic 
placement of intraaonic balloons Immediately before starting the 
B 
procedure. This adult patlent tolerated this modification and sur-
vlVed the operation With a blood loss 01 26 units. In a pediatnc 
patient With juvemle polypo~ls and a normal liver. the liver was 
omitted from the multiviscerail-.'TufL tFig. lel. Her rectum was re-
constructed by a pul!-throu~h techmque. Kidnevs were included with 
the multivisceral grafts in another pedlatnc patient who had renal 
i nsutliciency t Fig. 1 Dl. 
PostoperatIVe mana~emlDntK Management of multivisceral trans-
plant reCIpients after transplantation was the same as for isolated 
intestmal recIpients. mcluding methods of nutntlonal management 
and prevention of inlection. FK506. sterOids. and prostaglandin E 1 
(ProstinJ were used for immunosuppre~slonK Intravenous FK506 /0.1 
• 
• 
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to 0.15 mglkg/day) was started intraoperatively, and was then 
switched to oral FK506 <0.3 mg/kg/day or slightly less) when the 
patient became tolerant to enteral feeding. Trough plasma levels of 
FK506 were maintained at 2-3 ng/ml for the first month. 1-2 ng/ml 
until the third month. and 1 ng/ml thereafter (Fig. 2). Methylpred-
nisolone 1 g in adults or hydrocortisone In children was given intra-
venously immediately after the grafts were revascularized and was 
followed by rapid tapering of predonisone over 5 days after trans-
plantation. Maintenance prostaglandin El <0.6 to 0.8 ~g/kg/hrF was 
continued until intravenous FK506 was stopped. 
:VIonitoring of intestinal graft rejection was based on clinical find-
ings, endoscopic examination, and histopathological study of endo-
scope-guided biopsies. Treatment of intestinal rejection depended 
upon its severity as described before (8). Routine liver function tests 
were used to monitor liver rejection. and liver biopsies were taken if 
needed. Frequent measurements of amylase and lipase levels in 
blood and/or fluid in Jackson-Pratt drains were used to monitor 
pancreas rejection. 
Assessment of graft function. Body weight, volume of stool output. 
frequency and nature of the stool. and dependency on TPN, enteral 
feeding, and/or oral diet were repeatedly evaluated to assess intes-
tinal graft function. In addition. absorptive function was directly 
measured by D-xylose test and by 72-hr fecal fat secretion. Measure-
ments of gastric emptying by radiolabeled test meals. intestinal tran-
sit time by a barium follow-through, and contractile activity by ma-
nometry were perfonned periodically to detennine the motility of the 
gastrointestinal tract. Graft function of the liver and the pancreas 
was detennined by serial determination of blood chemistries. Pan-
creatic endocrine function was periodically studied in long-tenn sur-
vivors by measuring blood glucose and c-peptide levels after intra-
venous injection of 0.5 g/kg glucose. 
RESULTS 
Survival. Of the 13 patients, 6/10 given primary grafts and 
1/3 in which the multi visceral procedure was secondary are 
currently alive and well with follow-up of 9 to 31 postopera-
tive months (Tables 1 and 2). Six are at home while one 
pediatric patient is currently hospitalized for the treatment 
of posttransplant lymphoproliferative disease (PTLDl; this 
last patient's antidonor lymphocytotoxic crossmatch was 
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positive. With an actual patient survival of 7/13 (53.8o/cl, the 
actuarial patient survival rates by the life-table method at 3 
months, 6 months. one year. and 2 years are 76.9%, 69.2'7c. 
53.8%, and 53.8%, respectively. 
Causes of'mortality. The 6 deaths occurred 1.5,2,2,5,6.5. 
and 6.5 months after the multi visceral transplantation 
(Table 1), Three of the 6 deaths were caused by PTLD, one by 
respiratory failure, one by rejection, and one by sepsis (Table 
1). Two of the 3 deaths caused by PTLD occurred at 49 days 
and 198 days after primary transplantation; the third was 57 
days after replacement of a rejected combined liver-intestine 
graft. In the last case, the rejection had followed reduction of 
immunosuppression at 10 months for the treatment of PTLD 
in the donor colon after the primary transplantation. At the 
time of the rescue multivisceral transplantation 15 months 
following the primary procedure, no PTLD lesions were de-
tectable in the specimen or elsewhere. 
Patient 8, who died from cytomegalovirus (CMV) infection. 
was CMV seronegative pretransplant and received grafts 
from a CMV-seropositive donor: although the infection was 
controlled, the lungs were destroyed. Patient 12, who was 
rescued from rejection of her isolated intestinal graft. was 
found to have a resistant intraabdominal infection with Toru-
lopsis glabrata in the abdominal cavity at the time ofretrans-
plantation and died from this 5 months later. 
Rejection. Ileal biopsies collected via the terminal ileos-
tomy or the Bishop-Koop ileostomy showed rejection in 11 
(84.6%) of the 13 recipients. On 162 occasions, the ileal biop-
sies were taken simultaneously with sampling from other 
sites: stomach (n=50), duodenum and/or jejunum (n=27), or 
colon (n=85). When the ileum had histological evidence of 
acute rejection, rejection was also found at the aforemen-
tioned sites at 0% (0/3). 25% (218), and 43.7% (7/16), respec-
tively. Isolated rejection at these sites was found only once, at 
the jejunum in patient 7. Acute rejection of the stomach was 
never seen. 
Rejection of the liver and the pancreas was less frequent 
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FIGURE 2. Immunosuppression and liver and kidney function. Values expressed as median. (A) Pediatric patients: IB) Adult pauents_ 
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TABLE 2. Current status of 7 survivors 
Graft functlon 
Survivalb 
'days! 
GastrOintestine Liver Pancreas 
,\ge Location 
TPN Stool d·xylose Imgldll 
fecal fat 
excretion 
('7d 
GOT T. bil Blood sugar 
lUlL) \ mgldl) (mgldl) Treatment 
1 32.6 994 Home Free 
2 24.3 717 Home Free 
4 31.5 641 Home Free 
5 4.5 559 Home Free 
9 1.8 420 Hospital' Free 
Formed 
Formed 
Formed 
Formed 
Formed 
32.S 
23.7 
34.1 
26.9 
32.8 
48.2 30 
62.6 23 
23.5 44 
15.9 85 
50 
0.5 121 
0.3 225 Anti-DM agent 
1.0 72 
0.5 78 
0.3 75 
11 10.9 355 Home Free Formed 
12 34.9 281 Home Free Formed 
• As shown in Table 1. 
b As of May 15. 1994. 
, Under treatment for PI'LD. 
and serious, with an incidence by clinical criteria of 46.2% 
(6/13) for the liver and 30.1% (4113) for the pancreas. In-
creased immunosuppression for liver rejection was not re-
quired. but severe acute pancreatitis was caused by rejection 
in one patient after immunosuppression had been reduced. 
No evidence of graft-versus-host disease (GVHD) was de-
tected clinically or in the tissue samples (including 3 post-
mortems) in any of the cases. 
Complications. All recipients. except patient 9, had signifi-
cant or life-threatening complications (Table 3), of which the 
6 examples ofPTLD were the most common. Of the 3 patients 
who survived PTLD, 2 have resolved lesions and the third is 
improving. The 5 intraabdominal abscesses were caused by 
leakage from the gastrostomy site (n = 1), enteric perforation 
(n=2), and necrotizing pancreatitis (n=2)' The pancreatic 
abscesses were apparently caused by preservation; one pa-
tient underwent total pancreatectomy (patient 8) and the 
other distal pancreatectomy (patient 11l. Patient 12, who had 
necrosis and scarring at the muscle layer of the intestinal 
wall. required 5 separate enteric resections after each of 5 
perforations over a time span of 1.5 months. Two adult re-
cipients required transient dialysis for renal failure to which 
FK506 and nephrotoxic antibiotics appeared to be contribu-
tory (Figure :2)' A persistent elevation of cannulicular en-
zymes from ampullary dysfunction in patient :2 was relieved 
with endoscopic papillotomy, while another patient with this 
complication did not require intervention. 
During the early postoperative period. enteric microorgan-
isms. including Enterococcus {aecium, Enterococcus (aecalis. 
26.4 28 0.2 53 
39 0.6 126 Insulin <1S Ulday) 
Escherichia coli, and Klebsiela, were cultured from the peri-
toneal fluid andlor wound discharge of 12 (92.3%) of the 13 
patients, in the sputum andlor bronchoalveolar lavage of 9 
(69.2%), and in the blood and/or catheters of 12 (92.3%). All of 
the recipients who survived for more than 2 months after 
surgery developed a nonnal bacterial flora of the stool with 
bacterial overgrowth with> 109 colony fonning units/ml. 
Graft function. All 7 surviving recipients as well as pa-
tients who died after more than 3 months gained or main-
tained their body weight exclusively on an unrestricted oral 
diet (Table 2). Among the current survivors, the latest D-
xylose absorption test was nonnal in all studied, but fecal fat 
excretion was universally elevated, especially in patient 2 
who had 2 episodes of pancreas rejection. Motility function of 
the gastrointestinal tract was highly variable, and was influ-
enced by the duration of follow-up. The trend in long survi-
vors suggested recovery of nonnal gastric emptying and in-
testinal transit after one year (Fig. 3). However, manometric 
studies commonly showed that antral and intestinal contrac-
tions were hypoactive during fasting and after feeding, with 
absent migrating motor complex propagation, even later 
than one year. 
Liver function is normal or near-nonnal in all of the sur-
viving patients. Two of them require treatment for hypergly-
cemia caused by distal pancreatectomy (patient 11) or pan-
creas rejection (patient :2}-{)ne with insulin and the other 
without. Changes in blood glucose and C-peptide in these :2 
patients during an intravenous glucose tolerance test are 
shown in Figure 4. 
TABLE 3. Complications 
~lajor: 
PTLD 
Abdominal abscess 
Renal failure 
Pancreatitis 
Ampullary dysfunction 
[nfectious: ' 
Abdomen 
Lung 
Blood 
Bactenal overgrowth 
, Cases are shown in Table l. 
Patients li1-) 
6 (46.2'7c) 
5 (38.5'7cl 
3 (23.1'7c) 
3 (23.1,}) 
2 rl5.4'7c) 
12 (92.3,}) 
9 (69.2,}) 
12 (92.3,}) 
11 (84.6<':;-) 
, Positive culture of enteric microorgarusms. 
Comments ICase!' 
Died (cases 3. 7, & 12), resolved (cases :.1 & S). resolving (case 9) 
Due to intestinal perforation (cases 9 & 14), pancreatitis 
(cases 10 & 13). intestinal leakage (case 7l 
Required transient dialysis (cases 1 & 4) 
Due to preservatIOn injury I cases 10 & 13). rejection (case 2) 
Required endoscopic papillotomy (case ;.1) 
Wound. J-P drain, or discharge 
Sputum or bronchoalveolar lavage 
Blood or lines 
> lOv CFUlml by stool culture 
i 
• 
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FIGURE 3. Blood level of glucose and C-peptide after intravenous 
glucose tolerance test. Glucose was given at a dose of 0.5 mg/kg. 
Shaded areas indicate range obtained from 5 normal controls. POD: 
postoperative days. 
FIGURE 4. Barium follow-through of multivisceral recipient (patient 
10). (A) 30 min: (S) 2 hr: (C) 3 hr: tD) 4 hr. 
DISCUSSION 
Our experience and that of others with multivisceral (3-6, 
8, 9), liver-intestinal (7, 8, 12). and isolated intestinal ( 13-
15) transplantation have delineated what can and cannot be 
achieved with all 3 of these procedures using current man-
agement methods. As with liver transplantation through the 
1970s. the procedures that include intestine are feasible but 
impractical means of therapy that are not yet ready for gen-
eral use. Although half the multivisceral recipients were re-
stored to near normal health. including relatively complete 
dietary rehabilitatlOn. the early and late mortality was ex-
cessive. with a lengthy list of complications even for patients 
who successfully ran the gauntlet of the first postoperative 
year. 
The problems were much the same as those still seen with 
conventional liver transplantation. but they have been far 
more frequent and serious: incomplete control of rejection 
with consequent bacterial translocation throughout the dam-
aged intestinal graft. a high rate of lethal septic complica-
tions. and the extraordinary 46% incidence of lymphoprolif-
erative disorders. The most encouraging notation was the 
total absence ofGVHD. which was feared at one time to make 
the intestine a forbidden organ for transplantation unless 
there was a perfect MHC match (16). 
The next large advance is predicted to turn on a strategy 
that would have been an inconceivable proposal with the 
previous paradigm of transplantation immunology. However. 
the freedom from GVHD of these and other kinds of human 
intestinal recipients (7-9) can now be explained by the mu-
tually canceling interactions of the coexisting cell popula-
tions following the transplantation of any whole organ that 
we have postulated to be the seminal mechanism of graft 
acceptance (17, 18). Lymphoid depletion of the graft. which 
was the consensus of workers in the intestinal transplanta-
tion field until recently ( 19-22), unbalances the graft-host-
immunologic relation and appears to us to be unnecessary 
and probably contraindicated. When T cell depletion of the 
intestine was attempted in earlier clinical cases. there was 
an almost universal incidence of B cell lymphomas (3.4, 6l. 
Armed with the realization that persistent spontaneous 
chimerism begins within minutes by migration of donor non-
parenchymal cells from all grafts. and most dramatically 
from organs with a large hematolymphopoietic constituency, 
this timing has been simulated by peri operative infusion of 
3x 10g/kg unaltered bone marrow cells in 45 consecutive un-
conditioned human recipients of kidneys, livers. hearts. and 
lungs under conventional FK506-prednisone immunosup-
pression. The freedom of these patients from GVHD (trivial 
only in 2). their benignancy of recovery I all are weill, and the 
demonstration of stable macrochimerism 10 the first 18 after 
.j, to 17 months (23) has generated plans to use the same 
treatment protocols for future intestinal recipients. 
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CENTRAL NERVOUS SYSTEM LYMPHOMAS IN ORGAN 
ALLOGRAFT RECIPIENTS1,2 
ISRAEL PENN3 AND GIL PORAT 
Department of'Surgery, UniverSity of' Cincinnati Medical Center. Cincinnati. 45267·0558; and Cincinnati \{>terans Affairs 
Medical Center. Cincinnati. Ohio 45220 
Central nervous system (CNS) involvement occurred 
in 289 of 1332 patients (22%) with posttransplant non-
Hodgkins lymphomas. The average time of appear-
ance was 33 months (range 3 weeks to 248.5 months) 
posttransplantation. Lesions were confined to the 
CNS in 159 patients (55%), while 130 (45%) had involve-
ment of other organs. Lesions involved the brain in 254 
patients (88%), the brain and spinal cord in 5 (2%), the 
spinal cord in 2 (I %), unspecified locations in the CNS 
in 13 (4%), the meninges in 8 (3%), and the cerebrospi-
nal fluid (CSF) in 7 (2%). All patients whose only in-
volvement of the CNS was of the meninges or CSF had 
lymphomas involving multiple organs. Many tumors 
(48%) appeared within one year after transplantation. 
Brain lesions were frequently multicentric in distribu-
tion. Ninety-one (31%) of the 289 patients had no treat-
1 Pre!lented at the 20th Annual Meeting of the American Society of 
Transplant Surgeons. May 18-20. 1994. Chicago, IL. 
l Supported. in part by a grant from the Department of Veterans 
Affairs. 
J Address correspondence to Israel Penn. M.D .. Dept. of Surgery. 
Univ. of Cincinnati. 231 Bethesda Ave .• Cincinnati. OR 45267-0558. 
ment and died, 70 (77%) of their malignancies and 21 
(23%) from other causes. Of 198 patients who received 
treatment 124 (63%) died of their malignancies; 40 
(200/0) died of other causes, including 17 patients who 
had had complete remissions following treatment; 22 
(11%) are currently alive and in complete remission; 
and 12 (6%) are alive and still undergoing therapy. The 
treatment of choice is local radiotherapy to the brain. 
which either alone (18 patients) or in combination 
with other modalities (14 patients) caused 32 of the 39 
(82%) complete remissions. Ten of 30 patients with dis-
ease localized to the CNS survived more than 5 years. 
including 6 who survived more than 10 years. eNS 
lymphomas should be suspected whenever a trans-
plant patient has neurologic symptoms however mi-
nor. and prompt work-up is essential to eliminate 
other possible causes. The dismal prognosis can be 
improved only by early diagnosis and prompt therapy. 
The lymphomas are the most important group of all ma-
lignancies that occur de novo in organ transplant recipients. 
If nonmelanoma skin cancers and in situ carcinomas of the 
uterine cervix are excluded. as they are from most cancer 
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